Top Story Today
Lilly Bets $7 Billion That Your Body Is the Best CAR-T Factory
Eli Lilly is paying up to $7 billion to acquire Kelonia Therapeutics and its platform for building CAR-T cells inside a patient's body, no factory required. The deal ($3.25 billion upfront, $3.75 billion in milestones) buys a single Phase 1 program and an in vivo gene-delivery system that uses engineered lentiviral particles to reprogram T cells in the bloodstream. Combined with AbbVie's $2.1 billion Capstan deal, Big Pharma has now committed over $9 billion to in vivo CAR-T startups in a matter of months. Kelonia's lead program targets multiple myeloma, but Lilly's real prize is the platform itself.
Why it matters: Two separate pharma giants spending a combined $9.1 billion on in vivo CAR-T startups signals the industry believes cell therapy's future looks more like a single injection than a six-week factory process, a shift that could dramatically expand who gets access to these treatments.
Read more →Deals and M&A
argenx Writes a $2.2 Billion Check to Escape One-Drug Dependence
With its Vyvgart franchise printing $4.2 billion in annual sales, argenx is spending $2.2 billion in cash to buy Forte Biosciences and its anti-CD122 antibody, FB102. The drug selectively dials down aggressive immune cells while leaving the body's peacekeepers intact, with early positive data in vitiligo and celiac disease. Analysts called it a "pipeline-in-a-product" opportunity, though paying this much for Phase 1b data raised some eyebrows.
Read more →Lilly Spends $2.3 Billion on a Drug Class the FDA Flagged for Heart Risks
Lilly's second big deal this week: up to $2.3 billion for Ajax Therapeutics and its Type II JAK2 inhibitor. Unlike current JAK drugs (which carry FDA boxed warnings for cardiovascular and cancer risks), Ajax's approach targets the enzyme in its inactive state, potentially sidestepping the safety baggage. The Phase 1 drug treats myelofibrosis patients who failed existing JAK inhibitors. Lilly was a founding investor, making this less a cold call and more a long courtship.
Read more →Tarsus Bets $800 Million on a Disease With Zero Approved Treatments
Tarsus Pharmaceuticals is acquiring Alkeus for up to $800 million to gain gildeuretinol, a late-stage oral therapy for Stargardt disease, the most common inherited childhood macular dystrophy. No treatment currently exists for the roughly 30,000 Americans affected. With XDEMVY generating 93% gross margins, Tarsus has the cash to make this rare-disease land grab.
Read more →Pathos AI Drops $2.2 Billion on a Chinese Cancer Drug, Then Signs AstraZeneca
Pathos AI licensed Alphamab's JSKN016 (a bispecific ADC already in Phase 3 for triple-negative breast cancer) in a deal worth up to approximately $2.218 billion ($125 million upfront plus up to $2.093 billion in milestones), then inked an AstraZeneca partnership for a preclinical breast cancer PROTAC. The company claims its AI platform identified JSKN016 as a high-value asset; skeptics note the AI played matchmaker, not inventor. Proof still lies ahead.
Read more →Science and Regulatory
Intellia Says It Cracked the CRISPR Liver Toxicity Case
After a Grade 4 liver injury paused two late-stage trials last fall, Intellia announced it identified the root cause of the toxicity in its CRISPR gene-editing program. The delayed onset (nearly a month after dosing) pointed toward the gene target itself rather than the delivery vehicle, which could mean the rest of Intellia's platform is safe. Evercore upgraded the stock to Outperform, though Goldman Sachs still holds a Sell rating.
Read more →FDA Approves First CRISPR Gene Therapy for Toddlers With Sickle Cell
Vertex's Casgevy became the first gene therapy approved for sickle cell patients as young as two, down from the previous age limit of 12. In trials, all four evaluable children (out of 11 dosed) went crisis-free for at least 12 months. The catch: a $2.2 million price tag for a patient population that's over 90% Black and disproportionately covered by Medicaid. The science is here; the access question is wide open.
Read more →The First Circular RNA In Vivo CAR-T Therapy Just Reached the Clinic
RiboX Therapeutics won FDA clearance to test RXIM002, the first circular RNA-based in vivo CAR-T therapy in humans. The approach delivers genetic instructions via targeted lipid nanoparticles, programming T cells inside the body with a single injection. Circular RNA's closed-loop structure lasts longer than standard mRNA, potentially producing steadier CAR expression. The Phase 1 trial starts in autoimmune cytopenias.
Read more →Policy and Geopolitics
Uncle Sam Opens a Formal Investigation Into China's Biotech Subsidies
The U.S. International Trade Commission launched a probe into whether Chinese state subsidies are warping biotech competition across genomic sequencing, synthetic biology, and drug ingredient manufacturing. The report drops January 2027 and could fuel tariffs, procurement bans, or new legislation. A large majority of U.S. biotech firms had ties to at least one Chinese CDMO in 2025, making supply chain diversification an urgent priority.
Read more →